Ironwood Pharmaceuticals (IRWD) Piper Sandler 36th Annual Healthcare Conference summary

Capital structure and financial strategy

• Reduced debt from $800M to $600M over five quarters, focusing on further paydown using cash flows from LINZESS.

• Targeting accelerated debt reduction in 2026 with the anticipated launch of apraglutide.

• No specific net leverage target disclosed, but intent to lower ratio quickly.

LINZESS performance and strategy

• LINZESS maintains over 50% market share, with 10–12% annual prescription growth and strong demand.

• Facing headwinds from legislative changes and IRA-related pricing, with profitability prioritized over net sales.

• Contracting strategy is shifting away from exclusivity, with changes expected to impact 2026–2028.

• Evaluating DTC and personal promotion spend to maximize commercial margins.

• Exploring an OTC pathway as a future revenue stream, working with the FDA and AbbVie.

Apraglutide market opportunity and development

• Addressable market for short bowel syndrome validated at 8,000–12,000 patients, split evenly between stoma and colon-in-continuity.

• Two-thirds of patients are treatment-naive to GLP-2; once-weekly dosing seen as a key differentiator.

• NDA rolling submission to begin imminently, with full submission expected by end of Q1 and a planned early 2026 launch.

• Anticipates broad indication for both stoma and CIC populations, supported by robust clinical data.

• Clinical data show significant reduction in parenteral support, with strong physician and patient interest.